144 articles - From Friday Aug 12 2022 to Friday Aug 19 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
| Am J Gastroenterol |
Recognizing and Defining Occasional Constipation: Expert Consensus Recommendations. Prospective studies are required to validate this definition and determine OC prevalence in the community. This review highlights current knowledge gaps and could provide impetus for future research to facilitate improved understanding of OC and development of evidence-based management guidelines. |
| Gastrointest Endosc |
Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference. We expect that with ongoing research, higher-quality evidence will be obtained to enable creation of a guideline for these issues. We further anticipate that forthcoming expert-generated and agreed-on statements will provide valuable practice advice on the role and use of endoscopy in patients with EoE. |
meta-analyses and systematic reviews
| Aliment Pharmacol Ther |
Meta-analysis: hepatitis B reactivation in patients receiving biological therapy. HBVr prevalence rates differ between the chronic carrier state and the occult carrier state. The uptake of prophylactic antiviral therapy in high-risk groups was low, contrary to clinical practice guidelines. |
| Am J Gastroenterol |
OUTCOMES OF EXERCISE INTERVENTIONS IN PATIENTS WITH ADVANCED LIVER DISEASE: A SYSTEMATIC REVIEW OF RANDOMIZED CLINICAL TRIALS. A review of eleven randomized clinical trials with 358 participants with advanced liver disease demonstrates that exercise interventions can have favorable outcomes on muscular/cardiorespiratory fitness, and quality of life. While attrition and adherence varied, these interventions appear to be safe in patients with cirrhosis and are well tolerated. |
| Clin Gastroenterol Hepatol |
Estimating the global burden of Epstein-Barr virus associated gastric cancer: a systematic review and meta-analysis. Assuming a causal association between EBV and gastric cancer, our findings, when applied to the GLOBOCAN 2020 gastric cancer incidence, suggest that primary prevention such as the development of an effective EBV vaccine might prevent 81 000 EBV-associated gastric cancer cases worldwide annually. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
Autoimmune hepatitis and metabolic syndrome-associated disease development: a U.S. cohort study. In the largest US-based cohort of patients newly diagnosed with AIH, there was a considerable burden of pre-existing and de novo MSADs that may affect AIH treatment outcomes. Identifying those at highest risk of co-morbid MSADs allows for an individualised approach to management to reduce its long-term sequelae in patients with AIH. |
| Am J Gastroenterol |
A combined Baveno VII and spleen stiffness algorithm to improve the non-invasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease. The addition of SSM significantly improves the clinical applicability of the algorithm based on LSM and platelet count for CSPH diagnosis. Our models can be used to non-invasively identify candidates for non-selective beta-blocker treatment and patients at high-risk of decompensation. |
A freshwater fish-based diet alleviates liver steatosis by modulating gut microbiota and metabolites: a clinical randomized controlled trial in Chinese patients with nonalcoholic fatty liver disease. Higher intake of freshwater fish may be beneficial to NAFLD by regulating gut microbiota and its metabolites, whereas intake of the similar total of animal protein and fat from the alternating freshwater fish and red meat may not be harmful to NAFLD in the dietary management of NAFLD patients. |
A Novel Convolutional Neural Network Model as an Alternative Approach to Bowel Preparation Evaluation Before Colonoscopy in the COVID-19 Era: A Multicenter, Single-Blinded, Randomized Study. The novel AI-CNN model, which demonstrated comparable outcomes to the routine practice, may serve as an alternative approach for evaluating bowel preparation quality before colonoscopy. |
A novel SAVE score to stratify decompensation risk in compensated advanced chronic liver disease: an international multicenter cohort study. The SAVE score can be readily incorporated into clinical practice to accurately predict the individual risk of hepatic decompensation in cACLD. |
An Endoscopic and Histologic Study on Healing of Radiofrequency Ablation Wounds in Patients with Barrett's Esophagus. RFA wounds in BE are re-epithelialized, not just by squamous cells from the proximal wound margin, but by scattered squamous islands in which ESMG duct cells appear to re-differentiate into the squamous progenitors that fuel squamous re-epithelialization. SSIM can be found in most patients during the healing process. We speculate that this SSIM might underlie Barrett's recurrences after apparently successful eradication. |
ANEMIA ETIOLOGY AND THE RESPONSE TO A GLUTEN-FREE DIET IN UNTREATED PATIENTS WITH CELIAC DISEASE: A 2-YEAR FOLLOW-UP. The anemia etiology included iron deficiency, vitamin deficiencies, and anemia of chronic diseases. The majority of patients will normalize their Hb levels and the anemia laboratory parameters one year after starting a strict GFD. |
ASSOCIATION OF CELIAC SEROLOGY NORMALIZATION WITH THE RISK OF HYPOTHYROIDISM: A COHORT STUDY. In this retrospective, age-stratified analysis, we report that persistent-positive serology may be associated with the risk of hypothyroidism among the pediatric population. Prospective cohorts are needed to validate our findings. |
Celiac disease and serious infections: A nationwide cohort study from 2002-2017. This nationwide study of celiac patients diagnosed in the 21st century revealed a significantly increased risk of serious infections. While absolute risks were modest, vaccinations should be considered during CD follow-up care. |
Comparative performance of 14 HCC prediction models in CHB: a dynamic validation at serial on-treatment timepoints. In this undergoing antiviral treatment CHB cohort, most HCC prediction models performed well even using on-treatment values during first 2 years, particularly REAL-B, AASL-HCC, CAMD and mPAGE-B model. |
Comparing predicted probability of hepatocellular carcinoma in cirrhosis patients to the general population: an opportunity to improve risk communication? The mean absolute risk difference was 3.61%, ranging from 0.012 to 35.9%. An online HCC-GP comparison calculator for use by patients/clinicians is available at: a patient's predicted HCC probability to the general population is feasible and may help clinicians communicate risk information and encourage screening uptake. |
DIAGNOSTIC DELAY IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS HAS NOT CHANGED SINCE FIRST DESCRIPTION 30 YEARS AGO. DD has not changed since EoE's first description almost 30 years ago and remains substantial. Even today a third of patients has a persistently high DD of =10 years. Substantial efforts are warranted to increase awareness for EoE and its hallmark symptom, solid-food dysphagia, as an age-independent red-flag symptom amongst health-care professionals and presumable the general population alike in order to lower risk of long-term complications. |
Early-onset colorectal cancer incidence, staging and mortality in Canada: implications for population-based screening. Emerging data support future modifications to guidelines on screening for eoCRC in Canada. Further research is required on impact, cost-effectiveness, and risk prediction for targeted screening within this group. |
EFFICACY AND SAFETY OF INFLIXIMAB RETREATMENT: IN CROHN'S DISEASE:A MULTICENTRE, PROSPECTIVE, OBSERVATIONAL COHORT (REGAIN) STUDY. In this first prospective cohort study, IFX retreatment was safe and effective in one third of CD patients regardless the reason of prior discontinuation. Early detection of anti-drug antibodies can predict subsequent IFX reintroduction failure and infusion reactions. |
Evaluating the role of antibiotics in patients admitted to hospital with decompensated cirrhosis: lessons from the ATTIRE trial. Half of antibiotics at study entry were given to patients without an infection diagnosis which did not reduce overall risk of HAI or improve mortality. This supports prompt de-escalation or discontinuation of antibiotics guided by culture sensitivities at 24-48 hours after commencement if no infection and the patient is improving. |
Impact of Obesity on Risk of Hospitalization, Surgery and Serious Infection in Biologic-treated Patients with Inflammatory Bowel Diseases: A CA-IBD Cohort Study. In a multicenter, EHR-based cohort of biologic-treated patients with IBD, obesity was not associated with hospitalization, surgery, or serious infections. Further studies examining the impact of visceral obesity on patient-reported and endoscopic outcomes are needed. |
Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results from a Randomized Trial. No differences in outcomes were seen between IBD&me and the biologics fact sheet in this comparative effectiveness study; patients reported high satisfaction with both resources. Further study, particularly among biologic naïve patients, is needed to determine the utility of interactive components to IBD decision aids. |
Intra-pancreatic, liver, and skeletal muscle fat depositions in first attack of acute pancreatitis versus health. Increased IPFD may predispose to the development of acute pancreatitis. This opens up opportunities for reducing the burden of acute pancreatitis by means of primary prevention. |
Long Term Outcomes of the Six Food Elimination Diet and Food Reintroduction in a Large Cohort of Adults with Eosinophilic Esophagitis. This study describes the largest cohort reported of adult EoE patients completing SFED with food reintroduction. Overall SFED histologic response was 54% which increased to 58% with one additional round of diet therapy suggesting that 31% may respond on second attempt. Most patients who completed food reintroduction had a single food trigger identified. Dietary elimination with specific food trigger identification is a feasible alternative to medical therapy for adults with EoE. |
LOW PREVALENCE OF ENDOSCOPIC SCREENING FOR BARRETT'S ESOPHAGUS IN A SCREEN-ELIGIBLE PRIMARY CARE POPULATION. In this large, primary care population, only 39% of screen-eligible patients underwent EGD. A majority of exams were triggered by refractory symptoms rather than screening referrals, highlighting a need for improved dissemination and implementation of BE screening. |
OPTIMAL WIRELESS REFLUX MONITORING METRICS TO PREDICT DISCONTINUATION OF PROTON PUMP INHIBITOR THERAPY: Optimal Reflux Monitoring Metrics to Predict PPI Discontinuation. This clinical trial highlights the AET threshold of 4.0% as a high performing prognostic marker of PPI discontinuation.96-hrs of monitoring performed better than 48-hr, in predicting ability to discontinue PPI. These data can inform current diagnostic approaches for patients with GERD symptoms that are unresponsive to PPI therapy. |
Poor adherence to medical and dietary treatments in adult patients with eosinophilic esophagitis. Adherence to maintenance treatment is poor in many adult EoE patients. Clinicians should pay more attention to treatment adherence, particularly in younger patients, and discuss necessity of treatment. |
Prune juice containing sorbitol, pectin, and polyphenol ameliorates subjective complaints and hard feces while normalizing stool in chronic constipation: A randomized placebo-controlled trial. Prune juice exerted an effective and safe natural food therapy for chronic constipation. |
RESIST-HCV criteria to monitor progression of low-risk esophageal varices in patients with compensated cirrhosis after HCV eradication. The SIMPLE study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices. Biochemical-based RESIST-HCV criteria are useful to easily predict HRV development after HCV eradication by DAAs in patients with compensated cirrhosis and low-risk EV. |
Risk of Metachronous Advanced Neoplasia After Colonoscopy in Patients Aged 40-49 Years Compared to Patients Aged 50-59 Years. Compared to patients aged 50-59 years, patients aged 40-49 years may have a lower risk of developing metachronous AN when no adenoma is detected on index colonoscopy and a similar risk when NAA or AA is detected. These data suggest current surveillance colonoscopy guidelines may be applicable to patients aged 40-49 years who undergo colonoscopy. |
The association between non-steroidal anti-inflammatory drug use and inflammatory bowel disease exacerbations: a true association or residual bias? While we see an association between NSAIDs and IBD exacerbations using traditional methods, further analysis suggests this may be secondary to residual bias. These findings may reassure patients and clinicians considering NSAIDs as a non-opioid pain management option. |
The Effects of Modifying Amount and Type of Dietary Carbohydrates on Esophageal Acid Exposure Time and Esophageal Reflux Symptoms: A Randomized Controlled Trial. A modification of dietary carbohydrate intake that targeted a substantial reduction in the intakes of simple sugars improved pH monitoring outcomes and symptoms of GERD that profoundly affect daily life. These findings provide a feasible and clinically applicable contribution to the limited objective data existing for efficacious dietary recommendations in the routine treatment and management of GERD. Trail registration ClinicalTrials.gov NCT02384551. |
The Global Incidence of Peptic Ulcer Disease is Decreasing since the Turn of the 21st Century: A Study of the Organisation for Economic Co-operation and Development (OECD): Global Incidence of Peptic Ulcer Disease. PUD remains an important cause of hospitalization worldwide. Reassuringly, hospitalizations and mortality for PUD have consistently been falling in OECD countries in North America, Latin America, Europe, Asia, and Oceania. Identifying underlying factors driving these trends is essential to sustaining this downward momentum. |
The Incidence of Hepatitis E infection in American Patients with Suspected Drug-Induced Liver Injury is low and declining: The DILIN Prospective Study. Prior HEV infection is also most commonly seen in older individuals. Clinicians should consider testing for unsuspected acute HEV infection in older adult patients with acute hepatocellular DILI and jaundice. |
Transcutaneous Electrical Acustimulation Improves Irritable Bowel Syndrome with Constipation by Accelerating Colon Transit and Reducing Rectal Sensation via Autonomic Mechanisms. TEA improves constipation and symptoms of IBS by accelerating colon transit and reducing rectal sensation, possibly mediated via the autonomic mechanisms. |
Use of a cirrhosis admission order set improves adherence to quality metrics and may decrease hospital length of stay. Use of CDS in EHR-based interventions improves adherence to quality metrics for patients with cirrhosis and could easily be shared by institutions through EHR platforms. Further study and larger sample sizes are needed to better understand its impact on additional outcome measures. |
| Clin Gastroenterol Hepatol |
Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C). The risk-adapted approach is a feasible and cost-favorable strategy for population-based CRC screening, and therefore could complement the well-established one-time colonoscopy and annual repeated FIT screening strategies. |
PSYCHOTHERAPY FOR ALCOHOL USE DISORDER IS ASSOCIATED WITH REDUCED RISK OF INCIDENT ALCOHOL-ASSOCIATED LIVER DISEASE. The receipt of psychotherapy in the setting of AUD is associated with reduced incidence and progression of ALD. Given the safety and potential benefit of psychotherapy, clinicians should consider using it to prevent the development of ALD. |
Skeletal muscle-derived cell implantation for the treatment of faecal incontinence: a randomized, placebo-controlled study. Injection of a high dose of autologous skeletal muscle-derived cells followed by electrical stimulation significantly improved FI, particularly in patients with limited FI duration and high IEF at baseline and could become a valuable tool for treatment of FI, subject to confirmatory Phase III trial(s). Eudract number 2010-021463-32 ( |
The Prevalence, Humanistic Burden, and Healthcare Impact of Irritable Bowel Syndrome (IBS) Among United States Veterans. IBS is prevalent among Veterans and has a measurable impact on individuals and healthcare resources. Veterans with IBS may experience significant psychological impairment. |
Warfarin is associated with higher rates of upper but not lower gastrointestinal bleeding compared to direct oral anticoagulants: a population-based propensity-weighted cohort study. Warfarin was associated with higher rates of upper but not overall or lower GIB compared to DOACs. Warfarin was associated with higher rates of major GIB compared to apixaban. |
| Endoscopy |
| Gastroenterology |
Clinical and Genomic Characterization of Interval Colorectal Cancer in Three Prospective Cohorts. Interval CRCs had a significantly increased risk of death compared to screen detected CRCs that were not explained by established clinical prognostic factors, including stage at diagnosis. The survival disadvantage of interval CRCs did not appear to be explained by differences in the genomic landscape of tumors characterized by WES. |
Efficacy and Safety of Ivarmacitinib in Patients with Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Ivarmacitinib demonstrated clinical efficacy and was well tolerated in patients with moderate-to-severe, active, UC. Ivarmacitinib represents a promising new treatment for moderate-to-severe UC. |
The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study. In Denmark, the incidence and prevalence of IBD have increased over the last two decades. The IBD population is shifting towards an older age. These findings have implications towards understanding environmental shifts as well as preparing healthcare systems for an aging IBD population. |
| Gastrointest Endosc |
Targeted next generation sequencing of endoscopic ultrasound-guided through-the-needle-biopsies from pancreatic cystic lesions. Thus, molecular analysis of TTNBs by NGS has high sensitivity and specificity for diagnosing mucinous cysts and IPMNs. Although the procedure comes with a risk of adverse events of 9.9 %, TTNBs are a robust alternative to cyst fluid for a combined histological and molecular diagnosis of PCLs. |
| Gut |
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulcerative colitis: a randomised controlled trial. Multidonor FMT with anti-inflammatory diet effectively induced deep remission in mild-moderate UC which was sustained with anti-inflammatory diet over 1year. |
Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Our large-sample multiomics data suggest that altered microbiome-metabolome interplay helps explain the pathogenesis of EO-CRC and LO-CRC. The potential of microbiome-derived biomarkers as promising non-invasive tools could be used for the accurate detection and distinction of individuals with EO-CRC. |
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections. The herein described preS1-HDAg immunotherapy is shown to be immunogenic and vaccine-induced antibodies are highly effective at preventing HBV and HDV (super)infection both in vitro and in vivo. Our vaccine can complement current and future therapies for the control of chronic HBV and HDV infection. |
| Hepatology |
Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation. Weight variation is strongly associated with radiological evolution after oral contraception discontinuation. A score of estrogen exposure, easily assessable in clinical practice at diagnosis, predicts regression of HCA. |
Clinical Trials in HDV: Measuring Success. These clinical benefits may include reducing the risk of progression to cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, and mortality. However, the optimal way to measure success in HDV clinical trials remains unknown and will continue to evolve. |
Intrahepatic paracrine signaling by CLCF1 ameliorates diet-induced NASH in mice. Hepatocyte-specific inactivation of LIFR accelerated NASH progression in mice, supporting an important role of intrahepatic cytokine signaling in maintaining tissue homeostasis under metabolic stress conditions. Together, this study sheds light on the molecular nature of intrahepatic paracrine signaling during NASH pathogenesis and uncovers potential targets for therapeutic intervention. |
Novel Adeno-Associated Virus (AAV) Serotype 2 Capsid Variants for Improved Liver-Directed Gene Therapy. A are the first AAV peptide display variants selected in immunocompetent mice with improved hepatocyte tropism and transduction efficiency. Since these features are maintained across species, MLIV variants provide remarkable potential for the translatability of therapeutic approaches from mice to men. |
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study. Genetically predicted alcohol frequency, elevated serum liver enzymes, poor physical condition, obesity traits, T2DM, and hypertension were associated with an increased risk of NAFLD, whereas higher education and HDL-cholesterol were associated with a decreased risk of NAFLD. |
| Inflamm Bowel Dis |
Patient-Reported Outcomes Correlate With Microbial Community Composition Independent of Mucosal Inflammation in Pediatric Inflammatory Bowel Disease. Microbial community composition correlated with PROs in both CD and UC. Metabolic pathways differed relative to PROs in UC, but not CD. Data suggest that microbiota may contribute to patient symptoms in IBD, in addition to effects of mucosal inflammation. |
| J Crohns Colitis |
Available methods for benefit-risk assessment: lessons for inflammatory bowel disease drugs. The risks and benefits of each medical therapy must be discussed with the patient and a shared decision-making process is recommended. Future initiatives should be developed to perform a benefit-risk assessment considering the characteristics of inflammatory bowel disease drugs. |
Risk prediction for complications in Inflammatory Bowel Disease surgery: External validation of the American College of Surgeons' National Surgical Quality Improvement Program Surgical Risk Calculator. The accuracy of risks calculated by the ACS NSQIP Surgical Risk Calculator was deemed insufficient for patients undergoing surgery for IBD, generally underestimating postoperative risks. Recalibration or additional variables could be necessary to predict risks in this cohort. |
| J Hepatol |
Head to head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. MEFIB was better than MAST and FAST for detection of significant fibrosis as well as "at risk" NASH. All three models provide utility in risk stratification of NAFLD. |
| Neurogastroenterol Motil |
Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial. In women with IBS-D, vibegron was not associated with significant improvement in the percentage of API weekly responders. Vibegron was generally safe and well tolerated and, in particular, did not worsen IBS symptoms vs placebo. |
Type II achalasia with focal elevated pressures: A distinct manometric and clinical sub-group. We identified a distinct sub-group of type II achalasia on HRM, defined as type II achalasia with focal elevated pressures. This sub-group uniquely exhibits spastic features and may benefit from personalized treatment approaches. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Clin Gastroenterol Hepatol |
Management of Adults with Esophageal atresia. These include effects related to the underlying deformity such as atonicity of the esophageal segment, fistula recurrence and esophageal cancer to complications of the surgery including anastomotic stricture, gastroesophageal reflux and coping with an organ transposition. This review discusses the occurrence and management of these conditions in adulthood and the role of an effective transition from pediatric to adult care to optimize adult care treatment. |
| Gastroenterology |
| Gastrointest Endosc |
| Hepatology |
Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis. Our results emphasized the importance of mitochondrial oxidative stress, mtDNA damage and associated alterations in mitochondrial function and dynamics in the advanced fibrosis or cirrhosis in CHB and NASH. Mitochondria might be a target in drug development to stop fibrosis progression. |
| J Hepatol |
Current epidemiology of cholangiocarcinoma in western countries. In western countries, deaths due to intrahepatic cancers are rising at a higher rate compared to extrahepatic cancers. This may be due to rising cases of liver disease and misclassification of the different cancer types. |
| Neurogastroenterol Motil |
Hyoscine butylbromide mode of action on bowel motility: From pharmacology to clinical practice. However, since then, novel publications have appeared within the literature and also our knowledge of what represents normal motility in humans has evolved. Purpose This review is the result of the collaboration between a basic scientist and clinicians with the aim of providing an updated overview of the mechanisms of action of HBB and its clinical efficacy to guide not only use in clinical practice, but also future research. |
Letters to the editors and authors’ replies
| Clin Gastroenterol Hepatol |
| Gastroenterology |
| Gut |
| J Hepatol |
| Neurogastroenterol Motil |
all remaining publications eg case reports, images of the month, etc…
| Am J Gastroenterol |
| Clin Gastroenterol Hepatol |
| Gastroenterology |
| Gastrointest Endosc |
| Gut |
| Inflamm Bowel Dis |
| J Crohns Colitis |